Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Monoclonal antibodies: approved for Alzheimer’s disease but not without concerns While ... have been excluded from the trial. “Using active transport mechanisms to get these drugs across the ...

Childhood neuroblastoma is often a fatal disease. A new approach using a combination of two drugs shows promise in reducing ...

Following the success of the first generation of monoclonal antibody ... In addition, many third-generation antibodies designed to trigger different mechanisms of action simultaneously (such ...

Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.

Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.